Jazz Pharmaceuticals CEO Bruce Cozadd's 2019 pay jumps 29% to $15M
Jazz Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: June 12, 2020
Jazz Pharmaceuticals reported fiscal year 2019 executive compensation information on June 12, 2020.
In 2019, seven executives at Jazz Pharmaceuticals received on average a compensation package of $5.3M, a 1% decrease compared to previous year.
Average pay of disclosed executives at Jazz Pharmaceuticals
Bruce C. Cozadd, Chief Executive Officer, received $15M in total, which increased by 29% compared to 2018. 48% of Cozadd's compensation, or $7M, was in stock awards. Cozadd also received $1.3M in non-equity incentive plan, $5.4M in option awards, $1M in salary, as well as $13K in other compensation.
For fiscal year 2019, the median employee pay was $214,881 at Jazz Pharmaceuticals. Therefore, the ratio of Bruce C. Cozadd's pay to the median employee pay was 68 to one.
Daniel N. Swisher, Jr, Chief Operating Officer, received a compensation package of $4.7M, which decreased by 18% compared to previous year. 42% of the compensation package, or $2M, was in stock awards.
Robert Iannone, Executive Vice President, Research and Development, earned $3.7M in 2019.
Robert Ianonne, Chief Medical Officer, received $3.7M in 2019.
Robert Iannone, M.D., M.S.C.E, Executive Vice President, Global Head of Research and Development, earned $3.7M in 2019.
Matthew P. Young, Chief Financial Officer, received $3.6M in 2019, which increases by 7% compared to 2018.
Neena M. Patil, Senior Vice President and GC, earned $3.2M in 2019.
Related executives
Bruce Cozadd
Jazz Pharmaceuticals
Chief Executive Officer
Daniel Swisher
Jazz Pharmaceuticals
President
Matthew Young
Jazz Pharmaceuticals
Chief Financial Officer
Robert Iannone
Jazz Pharmaceuticals
Executive Vice President, Research and Development
Neena Patil
Jazz Pharmaceuticals
Senior Vice President and GC
Robert Ianonne
Jazz Pharmaceuticals
Chief Medical Officer
Robert MSCE
Jazz Pharmaceuticals
Executive Vice President, Global Head of Research and Development
You may also like
Source: SEC filing on June 12, 2020.